Thực trạng sử dụng thuốc sinh học trong điều trị viêm khớp dạng thấp tại Bệnh viện Đại học Y Hà Nội=Current state of biologics treatment in rheumatoid arthritis at Hanoi Medical University Hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Hoài Thu Phạm, Thị Hiền Phạm, Thu Hằng Phạm, Văn Tú Phạm, Huy Bình Trịnh

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Nghiên cứu y học (Đại học Y Hà Nội), 2024

Mô tả vật lý: tr.244-252

Bộ sưu tập: Metadata

ID: 244823

Thêm vào giỏ

Rheumatoid arthritis (RA) treatment has been revolutionized with the introduction of biological medications. To describe the current state of biologics use at Hanoi Medical University Hospital, a study was conducted on 99 inpatients who met the ACR/EULAR 2010 criteria for RA treated with biological medications from January 2023 to July 2024. Tocilizumab, an inhibitor of interleukin-6, was the most common biological medication selected to treat RA at 57.6%, followed by Golimumab, an anti-TNF-α group member at 24.2%... 56.6% of patients switched biological drugs, with 44.6% of those cases including two or more medications changes. Lack of responsiveness to treatment (46.4%) and insufficient drug supply (39.3%) were the primary causes of drug switching. Drug discontinuation and dose extension rates were 57.6% and 72.7%, respectively. Among the drug discontinuation group, 35.1%, 49.2% and 70.2% of patients stopped biological therapy after 6, 12 and 24 months, respectively. The majority of patients (49.1 and 38.9%, respectively) discontinued the medication or skipped doses because they could not afford to continue their therapy.Thuốc sinh học ra đời đã mở ra một cuộc cách mạng trong điều trị bệnh viêm khớp dạng thấp (VKDT). Với mục tiêu mô tả thực trạng sử dụng thuốc sinh học trong điều trị VKDT tại Bệnh viện Đại học Y Hà Nội, nghiên cứu của chúng tôi bao gồm 99 người bệnh được chẩn đoán VKDT theo tiêu chuẩn của EULAR/ACR 2010, điều trị bằng thuốc sinh học tại Bệnh viện Đại học Y Hà Nội từ tháng 1/2023 đến tháng 7/2024. Kết quả thu được thuốc sinh học được lựa chọn khởi đầu trong điều trị VKDT chiếm tỉ lệ cao nhất là Tocilizumab (57,6%), sau đó là Golimumab (24,2%)… Có 56,6% người bệnh đổi thuốc sinh học, trong đó 44,6% trường hợp đổi thuốc từ 2 lần trở lên. Các nguyên nhân chính dẫn đến tình trạng đổi thuốc là không đáp ứng điều trị (46,4%) và do thiếu nguồn cung ứng thuốc (39,3%). 57,6% người bệnh ngừng điều trị thuốc sinh học, trong đó tỷ lệ người bệnh ngừng điều trị trong 6 tháng, 12 tháng và 24 tháng lần lượt là 35,1%, 49,2%, 70,2%. Tỉ lệ người bệnh giãn liều thuốc là 72,7%. Phần lớn người bệnh ngừng thuốc hoặc giãn liều thuốc do vấn đề kinh tế với tỉ lệ là 49,1 và 38,9%.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR